Dueling IL-23 data drop as Lilly, J&J await FDA decisions in Crohn's

Eli Lilly and Johnson & Johnson unveiled competing data sets on Monday as they await FDA decisions on expanding the use of their IL-23 inhibitors – both approved within the past year for ulcerative colitis – to include Crohn's disease.